Table 1.
Clinical characteristics on admission of patients with PDRP
| Hyponatremic group (n = 27) | Normonatremic group (n = 72) | p-value | |
|---|---|---|---|
| Gender (M/F) |
10/17 |
48/24 |
0.015 |
| Age (years) |
49.1 ± 9.9 |
52.6 ± 11.7 |
0.173 |
| Duration of dialysis (years) |
4.0 ± 1.5 |
3.4 ± 1.8 |
0.148 |
| Primary renal disease |
|
|
|
| Chronic glomerulonephritis |
4 |
15 |
0.696 |
| Diabetic nephropathy |
9 |
28 |
0.783 |
| Hypertension |
8 |
13 |
0.328 |
| Systemic lupus erythematosus |
3 |
7 |
1.000 |
| Polycystic kidney disease |
0 |
1 |
1.000 |
| Unknown |
3 |
8 |
1.000 |
| Medication |
|
|
|
| Oral Hypoglycemic agent |
1 |
3 |
1.000 |
| α-adrenergic blocker |
6 |
8 |
0.197 |
| β-adrenergic blocker |
6 |
22 |
0.724 |
| Calcium channel blocker |
15 |
27 |
0.164 |
| ACEI or ARB+ |
5 |
7 |
0.185 |
| Furosemide |
2 |
6 |
1.000 |
| Na+ supplement |
0 |
0 |
1.000 |
| Number of 4.25% Dialysate (bags/day) |
1.2 ± 0.8 |
1.0 ± 0.7 |
0.144 |
| Duration before antibiotics delivery (day) |
1.1 ± 0.5 |
1.1 ± 0.8 |
0.148 |
| Co-morbidity: Deyo-CCI++ |
3.6 ± 1.2 |
3.7 ± 1.5 |
0.755 |
| Subjective global assessment score |
4.6 ± 1.2 |
5.7 ± 0.6 |
<0.001 |
| Nutritional status: mean nPNA* |
1.1 ± 0.3 |
1.2 ± 0.4 |
0.278 |
| RRF** (mL/min/1.73 m2) | 1.2 ± 1.4 | 1.5 ± 1.5 | 0.257 |
+ACEI or ARB, Angiorensin-convering enzyme inhibitor or Angiotensin-II receptor blocker, ++Deyo-CCI, Deyo-charlson comorbidity index, *mean nPNA (mg/kg/day), the 6-month average of normalized protein nitrogen appearance, **RRF, residual renal function.